Endocrine Abstracts

Introduction: Determining the radiation dose to both the kidneys and malignant lesions from therapeutic administrations of Y-90 DOTATOC is critical for optimal management of neuroendocrine cancer patients. Here, a new dosimetric approach uses PET/CT to quantify the absolute activity of Y-90 immediately after administration to calibrate subsequent tissue clearance monitored with bremsstrahlung SPECT. The dosimetric information is used to personalize subsequent Y-90 DOTATOC dose...

Background: Peptide Receptor Radionuclide Therapy (PRRT) is effective for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) and received FDA approval after demonstrating improved progression-free-survival (PFS) in advanced midgut NETs. We investigated a two-decade experience with PRRT, hypothesizing that PRRT confers PFS and overall-survival (OS) advantages in patients who progress after surgery.Methods: A single-institutional NET database was re...

Background: Peptide-based targeted alpha-particle radiotherapy has emerged as a promising approach to cancer treatment. 203Pb/212Pb is the only elementally identical isotope pair for this application. Tyr3-Octreotide (TOC) peptide ligands targeting SSTR2 have been widely investigated preclinically and clinically. [177Lu]DOTATATE was approved by the US FDA to treat patients with gastroenteropancreatic neuroendocrine tumors. However, t...